


GODAVARI FOUNDATION
GODAVARI COLLEGE OF NURSING JALGAON
EDUCATIONAL VISIT BY OTHER COLLEGES

2017-2018

SR NO.	NAME OF COLLEGES	VISIT	DATE
1	DR ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL JALGAON	UNIVERSITY EXAM	18-12-2018
2	DR ULHAS PATIL HOMEOPATHY COLLEGE JALGAON	FOR UNIVERSITY EXAM	18-12-2018





PRINCIPAL
Principal
Godavari College of Nursing
JALGAON

GODAVARI FOUNDATION
GODAVARI COLLEGE OF NURSING JALGAON
EDUCATIONAL VISIT BY OTHER COLLEGES

2018-2019

SR NO.	NAME OF COLLEGES	VISIT	DATE
1	DR ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL JALGAON	FOR UNIVERSITY EXAM	07-06-2019
2	DR ULHAS PATIL HOMEOPATHY COLLEGE JALGAON	FOR UNIVERSITY EXAM	07-06-2019
5	GOVERNMENT MEDICAL COLLEGE OF JALGAON	VISIT	03-08-2019





PRINCIPAL
Principal
Godavari College of Nursing
JALGAON

GODAVARI FOUNDATION
GODAVARI COLLEGE OF NURSING JALGAON
EDUCATIONAL VISIT BY OTHER COLLEGES

2019-2020

SR NO.	NAME OF COLLEGES	VISIT	DATE
1	DR ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL JALGAON	FOR UNIVERSITY EXAM	07-01-2020
2	DR ULHAS PATIL HOMEOPATHY COLLEGE JALGAON	FOR UNIVERSITY EXAM	07-01-2020
5	GOVERNMENT MEDICAL COLLEGE OF JALGAON	VISIT	03-08-2020




PRINCIPAL

Principal
Godavari College of Nursing
JALGAON

GODAVARI FOUNDATION
GODAVARI COLLEGE OF NURSING JALGAON
EDUCATIONAL VISIT BY OTHER COLLEGES

2020-2021

SR NO.	NAME OF COLLEGES	VISIT	DATE
1	DR ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL JALGAON	FOR RESEARCH PROJECT	08-02-2021
2	DR ULHAS PATIL HOMEOPATHY COLLEGE JALGAON	FOR UNIVERSITY EXAM	12-10-2021
4	DR ULHAS PATIL AGARICULTURE COLLEGE	FOR TREE PLANTATION	06-01-2021
5	GOVERNMENT MEDICAL COLLEGE OF JALGAON	VISIT	15-04-2020





-PRINCIPAL
Principal
Godavari College of Nursing
JALGAON

GODAVARI FOUNDATION
GODAVARI COLLEGE OF NURSING JALGAON
EDUCATIONAL VISIT BY OTHER COLLEGES

2021-2022

SR NO.	NAME OF COLLEGES	VISIT	DATE
1	DR ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL JALGAON	FOR RESEARCH PROJECT	08-02-2022
2	DR ULHAS PATIL HOMEOPATHY COLLEGE JALGAON	FOR UNIVERSITY EXAM	17-07-2022
3	DR ULHAS PATIL MEDICAL COLLEGE OF PHYSIOTHEREPY	YOGA SESSION/RESEARCH PROJECT	01-05-2021
4	DR ULHAS PATIL AGARICULTURE COLLEGE	FOR TREE PLANTATION	23-02-2021
5	GOVERNMENT MEDICAL COLLEGE OF JALGAON	VISIT	11-01-2022




PRINCIPAL
Godavari College of Nursing
JALGAON



Godavari Foundation's

Dr. Ulhas Patil Homoeopathic Medical College and Hospital, Jalgaon Kh.

N.H. No. 6, Jalgaon-Bhusawal Road, Jalgaon (Kh.)-425 309, Jalgaon (M.S.)

Tel. No.: 0257 - 2366683/84 Fax No.: 0257 - 2366648

Email Id : duphmchj@gmail.com Website : www.duphmc.ac.in

GF/DUPHMCHJ/Appointment/2021/ 667

Date: 12/10/2021

To,
Dr. Sumaiya Salim Shaikh
Assistant Professor
Medical Surgical Nursing (Neurosis)
Godavari College of Nursing
Jalgaon Kh.


Subject : Dr. Sumaiya Salim Shaikh is appointed as Senior Supervisor for Summer Examination 2021 at Godavari Foundation Dr. Ulhas Patil Homoeopathic Medical College & Hospital, Jalgaon Kh. from 12/10/2021.


Respected Madam,

With reference to above mentioned subject Godavari Foundation Dr. Ulhas Patil Homoeopathic Medical College & Hospital, Jalgaon Kh. has started Maharashtra University of Health Sciences, Nashik theory examination Summer 2021. You are appointed as Senior Supervisor from 12/10/2021 to 29/10/2021.


Please accept the appointment & join as early as possible.

Thanking You,




Dr. Dilip B. Patil
Principal
Dr. Ulhas Patil Homoeopathic Medical
College & Hospital, Jalgaon Kh.




Principal
Godavari College of Nursing
JALGAON



Godavari Foundation's

Dr. Ulhas Patil Homoeopathic Medical College and Hospital, Jalgaon Kh.

N.H. No. 6, Jalgaon-Bhusawal Road, Jalgaon (Kh.)-425 309, Jalgaon (M.S.)

Tel. No.: 0257 - 2366683/84 Fax No.: 0257 - 2366648

Email Id : duphmchj@gmail.com Website : www.duphmc.ac.in

GF/DUPHMC/HJ/Appointment/2022/ 660

Date: 28/02/2022

To,
Mr. Sumit Satish Nirmal
Assistant Professor
Mental Health Nursing (Psychiatric)
Godavari College of Nursing
Jalgaon Kh.

Subject : Mr. Sumit Satish Nirmal is appointed as Senior Supervisor for Winter Examination 2021 at Godavari Foundation Dr. Ulhas Patil Homoeopathic Medical College & Hospital, Jalgaon Kh. from 02/03/2022.

Respected Sir,

With reference to above mentioned subject Godavari Foundation Dr. Ulhas Patil Homoeopathic Medical College & Hospital, Jalgaon Kh. has started Maharashtra University of Health Sciences, Nashik theory examination Winter 2021. You are appointed as Senior Supervisor from 02/03/2022 to 16/03/2022.

Please accept the appointment & join as early as possible.

Thanking You,



Dr. Dilip B. Patil
Principal

Dr. Ulhas Patil Homoeopathic Medical
College & Hospital, Jalgaon Kh.



Principal
Godavari College of Nursing
JALGAON



INSTITUTIONAL ETHICS COMMITTEE

DR. ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL

JALGAON, DIST. JALGAON. 425309 MAHARASHTRA

OFFICE: Member Secretary-IEC, Dept. of Pharmacology

Phone. No. (Office) 0257-2366657 (Fax) 0257-2366648 Website. <http://www.dupmc.ac.in/>

Covering letter

Through Proper Channel Only

Date - 08.02.2022

To
The Chairperson,
IEC DUPMCH,
Jalgaon.

Sub: Submission of Synopsis of research protocol for Ethical Clearance.

Respected Sir/Madam,


I the undersigned, Dr/Mr/ Mrs. Anushka Ananda Khavare.....hereby submitting synopsis of my research protocol/ PG dissertation for ethical clearance. Kindly consider it for approval from ethics committee.

I am submitting herewith Title of Synopsis as mentioned below & as suggested by my aforesaid Guide.


Title of Synopsis

Change in attitude and perspective towards vaccination in health care professionals of tertiary care hospital after decrease in severity of covid-19 strain in country.

Kindly do the needful.


(Guide name and signature)

Dr. Rahul Prakash Bhavasar



Ms. Anushka A. Khavare
(Principal Investigator name and signature)

Ms.


(HOD name and Signature with Dept. seal)

Dr. Devendra R. Chaudhari

PROFESSOR & HOD
Dept. Of Pharmacology
Dr. Ulhas Patil Medical College,
& Hospital, Jalgaon Kh.


Principal
Godavari College of Nursing
JALGAON






INSTITUTIONAL ETHICS COMMITTEE
DR. ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL
JALGAON, DIST. JALGAON. 425309 MAHARASHTRA
OFFICE: Member Secretary-IEC, Dept. of Pharmacology
Phone. No. (Office) 0257-2366657 (Fax) 0257-2366648 Website. <http://www.dupmc.ac.in/>

APPLICATION FORM FOR PERMISSION (ETHICAL CLEARANCE)
OF RESEARCH PROJECT (BIOMEDICAL RESEARCH ON HUMAN)

N.B.:* To be submitted in TRIPLICATE. One copy will be returned to the department after approval.
(*To be preserved by IEC for minimum 15 years.)

1.	Title of the Research Project/ Dissertation Change in attitude & perspective towards vaccination in healthcare professionals of tertiary care hospital after decrease in severity of Covid 19 strain in country	Signature
2.	Name of the Principal Investigator/ Under/Post graduate student: Ms. Anushka Ananda Khavare	
3.	Name of the co-investigator/s (if applicable) i) ii) N.A. iii) iv)	N.A.
4.	Name of UG/PG guide Dr. Rahul Prakash Bhavasar	
5.	Name of Trial monitor / co-guide NA	N.A.
6.	HOD of Principal Investigator/UG/PG student: Dr. Devendra R. Chaudhari	(With seal) PROFESSOR & HOD Dept. Of Pharmacology Dr.Ulhas Patil Medical College, & Hospital, Jalgaon Kh.
7.	HOD of other Departments involved N.A.	(With seal) N.A.




Principal
Godavari College of Nursing
JALGAON

8.	Place where research work will be carried out	
	a. At DUPMC&	Yes / No ✓
	b. Outside DUPMC&H.	Yes / No ✓
	(Permission letter to be submitted if outside DUPMC&H)	Yes / No
9.	Time period required for completion of research project and it's analysis (Approximately)	From -To (Date)
	2 months	May - June 2022 2022
10.	Risk factor for the patient (give details):	
	A) Procedural	N.A.
	B) Adverse drug reaction (ADRs)	N.A.
	C) Invasive investigations (if any)	N.A.
	D) Explain the measures to counter the above risk factors.	N.A.

11.	Details about research project must include	Yes	No
	(a) Project title	✓	
	(b) Aims and objectives:	✓	
	(c) Introduction (Current knowledge about the research subject) shortly why you have chosen this topic	✓	
	(d) Materials and methods (Research plan and its implications)	✓	
	(e) Statistical analysis	✓	
	(f) Conflict of interest:	✓	
	(g) Risk factors:		✓
	(h) List of references:	✓	




Principal
 Godavari College of Nursing
 JALGAON




INSTITUTIONAL ETHICS COMMITTEE
DR. ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL
JALGAON, DIST. JALGAON. 425309 MAHARASHTRA
OFFICE: Member Secretary-IEC, Dept. of Pharmacology

Phone. No. (Office) 0257-2366657 (Fax) 0257-2366648 Website. <http://www.dupmc.ac.in/>

12.	Details of financial burden involved and how it will be met: N.A.	
13.	Whether the research project is sponsored:	Yes / No <input checked="" type="checkbox"/>
14.	Sponsoring authority: (mention the name) (1) Industry (2) Government (3) University (4) ICMR (5) Any other (give details). N.A.	
15.	Any other relevant information: N.A.	




Principal
Godavari College of Nursing
JALGAON

16. Enclosures:

		Attached	Not attached	Not applicable
1	Patient information sheet Part 1			✓
2	Informed consent form for subject participating in clinical trial (in English/Marathi/Hindi)	✓		
3	Case Record Form (CRF)			✓
4	Undertaking by the investigator	✓		
5	Stability testing of new drug			✓
6	Content of the proposed protocol for conducting clinical trial	X		✓
7	Data elements for reporting Serious ADR/ADE occurring in clinical trial.			✓
8	Study Flow Chart if any.			✓
9	Newspaper publication matter for subject recruitment if any.			✓
10	Funding details of sponsor or permission letter of other institutions if any, regulatory clearance like DCGI/FDA approval for drugs not marketed in India, ICMR approval for global multi-centric trial.			✓

(Attach 10 hard copies of enclosures + 10 hard copies of RESEARCH PROTOCOL and after IEC APPROVAL submit one soft copy to IEC, DUPMCH, JALGAON.)

I declare that I shall follow National and International Good Clinical Practice (GCP) guidelines in conducting the above clinical research project.


Anurag
Signature

Principal Investigator.

- 1) Principal Investigator should be prepared to give 10 minutes presentation on OHP/Power point to IEC when called.
- 2) Involved Traditional Medicine Doctor as Co-investigator for research on Traditional Medicine.



ma
Principal
Godavari College of Nursing
JALGAON



INSTITUTIONAL ETHICS COMMITTEE
DR. ULHAS PATIL MEDICAL COLLEGE AND HOSPITAL
JALGAON, DIST. JALGAON. 425309 MAHARASHTRA
OFFICE: Member Secretary-IEC, Dept. of Pharmacology


Phone. No. (Office) 0257-2366657 (Fax) 0257-2366648 Website. <http://www.dupmc.ac.in/>

(For IEC Office use only)


1	Sr. No given to project	03
2	Department	Pharmacology
3	Date of Receipt by IEC (submission of application)	08.02.2022
4	Date of resubmission to IEC	14.02.2022
5	Date of IEC meeting	14.02.2022
6	Decision of IEC: APPROVED/ RESUBMISSION/ REJECTED	14.02.2022
7	IEC decision conveyed on date	17.02.2022


CHAIRPERSON
IEC, DUPMCH




Dr. Nilesh Prakash Bendale.
MEMBER SECRETARY
IEC, DUPMCH




Principal
Godavari College of Nursing
JALGAON

1. Reference ID – 2022-09441

2. Title – Change in attitude and perspective towards vaccination in health care professionals of tertiary care hospital after decrease in severity of COVID 19 strain in country.

3. Introduction -

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative virus for the coronavirus disease 2019 (COVID-19) ongoing pandemic¹. The pandemic has resulted in a devastating impact worldwide, which prompted the need for mitigation policies to contain the pandemic². The ground strategy followed by most countries around the world was to reduce the transmissibility of the disease, often by non-pharmaceutical interventions (NPIs), including enforcing masks policy, hands sanitization, social distancing, travel restrictions, schools' closures, and partial or complete lockdowns². Vaccines are one of the most reliable and cost-effective public health interventions ever implemented that are saving millions of lives each year². There are several safe and effective vaccines that prevent people from getting seriously ill or dying from COVID-19³. This is one part of managing COVID-19, in addition to the main preventive measures³. Approved COVID-19 vaccines provide a high degree of protection against getting seriously ill and dying from the disease, although no vaccine is 100% protective³. All COVID-19 vaccines with WHO EUL are safe for most people 18 years and older, including those with pre-existing conditions of any kind, including auto-immune disorders. These conditions include: hypertension, diabetes, asthma, pulmonary, liver and kidney disease, as well as chronic infections that are stable and controlled³. The COVID-19 vaccines that are currently in development or have been approved are expected to provide at least some protection against new virus variants because these vaccines elicit a broad immune response involving a range of antibodies and cells⁴.



1. Reference ID – 2022-09441

2. Title – Change in attitude and perspective towards vaccination in health care professionals of tertiary care hospital after decrease in severity of COVID 19 strain in country.

3. Introduction -

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative virus for the coronavirus disease 2019 (COVID-19) ongoing pandemic¹. The pandemic has resulted in a devastating impact worldwide, which prompted the need for mitigation policies to contain the pandemic². The ground strategy followed by most countries around the world was to reduce the transmissibility of the disease, often by non-pharmaceutical interventions (NPIs), including enforcing masks policy, hands sanitization, social distancing, travel restrictions, schools' closures, and partial or complete lockdowns². Vaccines are one of the most reliable and cost-effective public health interventions ever implemented that are saving millions of lives each year². There are several safe and effective vaccines that prevent people from getting seriously ill or dying from COVID-19³. This is one part of managing COVID-19, in addition to the main preventive measures³. Approved COVID-19 vaccines provide a high degree of protection against getting seriously ill and dying from the disease, although no vaccine is 100% protective³. All COVID-19 vaccines with WHO EUL are safe for most people 18 years and older, including those with pre-existing conditions of any kind, including auto-immune disorders. These conditions include: hypertension, diabetes, asthma, pulmonary, liver and kidney disease, as well as chronic infections that are stable and controlled³. The COVID-19 vaccines that are currently in development or have been approved are expected to provide at least some protection against new virus variants because these vaccines elicit a broad immune response involving a range of antibodies and cells⁴.



Therefore, changes or mutations in the virus should not make vaccines completely ineffective⁴. In the event that any of these vaccines prove to be less effective against one or more variants, it will be possible to change the composition of the vaccines to protect against these variants⁴. Role of health care professional is vital in taking the decision regarding the vaccine. It is the health care professional who guides the government and to people to choose what is best among the available sources by analysing it and accordingly, it reflects in public who are at the benefit. So, any change attitude or perspective towards vaccination in health care professional will change the mind among the people and will be a good guideline for government for next step.

4. Objectives –

- (i) To evaluate the attitude towards vaccination during year 2020 and 2021 when severity was more of covid 19 strain.
- (ii) To evaluate the attitude towards vaccination now in year 2022 when severity of covid 19 strain has decreased.
- (iii) To evaluate the perspective towards vaccination during year 2020 and 2021 when severity was more of covid 19 strain.
- (iv) To evaluate the perspective towards vaccination now in year 2022 when severity of covid 19 strain has decreased.
- (v) To analyze change in attitude and perspective towards vaccination by comparing both from received data.

5. Materials and methods –

- (i) **Study design** — Questionnaire-based, Cross-sectional study
- (ii) **Type of study - Observational – analytical**

- (iii) **Study population** – Healthcare professionals of Medical, Nursing and Physiotherapy college of institution.
- (iv) **Sample size** – 250
- (v) **Selection criteria** –
- a. **Inclusion criteria** – health care professionals who are willing to give the information
 - b. **Exclusion criteria** - health care professionals who do not wish to give information
- (vi) **Study tool** – close end type, self-prepared questionnaire divided in to following groups
- a. Previous attitude
 - b. Recent attitude
 - c. Previous perspective
 - d. Recent perspective
 - e. General information regarding self-vaccination
- (vii) **Date collection** – Questionnaire answers will be collected by filling the form either manually or through google form, from healthcare professionals by personal visit or by sending it on WhatsApp group. Collected data will be kept confidential according to guidelines of Institutional Ethics Committee.
- (viii) **Total duration of study** – 2 months (after obtaining approval from the Institutional Ethics Committee)
- (ix) **Consent** – consent will be taken prior to the filling of the form.
- (x) **Statistical analysis** – Previous and recent attitude and perspective will be compared and will be analysed with general information regarding vaccination. Paired t-test

and unpaired t-test will be applied accordingly to compare among and in-between groups.

(xi) **Conflict of interest** – There is no conflict of interest.

6. **Implications** –

- (i) Any change in attitude and perspective in healthcare professional reflects in general population and government perspective towards the healthcare need.
- (ii) Any negative change can come up with disastrous loss in country, which can lead to downregulation of health and wealth of country.
- (iii) Positive attitude and perspective built up the Nation.
- (iv) Vaccination against covid 19 infection is today's need and should be continued to control the disease spread and improve immunity though not throughout life time but to control severity of it.
- (v) Positive attitude and perspective towards vaccination will increase the vaccination among children, pregnant ladies and will be effective for healthy generation.
- (vi) More such studies should be carried out by institutes for better decision.

7. **References** –

- (i) World Health Organization. WHO Coronavirus Disease (COVID-19) Health Topics: World Health Organization; 2022 [cited 2022 15 February]. Available from: <https://www.who.int/health-topics/coronavirus>.
- (ii) El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ (2021) Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. PLoS ONE 16(4): e0250555. <https://doi.org/10.1371/journal.pone.0250555>
- (iii) World Health Organization. WHO Coronavirus Disease (COVID-19) Vaccine: World Health Organization; 2022 [cited 2020 15 February]. Available from:

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice>.

(iv) World Health Organization. WHO Coronavirus Disease (COVID-19) News Room:

World Health Organization; 2022 [cited 2020 15 February]. Available from:

<https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines>.




Principal
Godavari College of Nursing
JALGAON

Undertaking by the Investigator:

1. Full name, Address and title of the Principal Investigator (or Investigators when there is no Principal Investigator)

MS. Anushka Ananda Phavare

303, svrat Apt, Hendrepada, Badlapur (W)

2. Name and address of the medical college, hospital or other facility where the clinical trial will be conducted: Education, training & experience that qualify the Investigator for the clinical trial (Attach details including Medical Council registration number, or any other statements of qualifications)

Dr. Ulhas Patil Medical College and Hospital, Jalgaon

3. Name and address of all clinical laboratory facilities to be used in the study.

N.A.

4. Name and address of the Ethics Committee that is responsible for approval and continuing review of the study.

IEC Dr. Ulhas Patil medical college

5. Names of the other members of the research team (Co-or sub-Investigators) who will be assisting the Investigator in the conduct of the investigations.

N.A.

6. Protocol Title and Study number (if any) of the clinical trial to be conducted by the Investigator.

change in attitude and perspective towards vaccination in healthcare professional of tertiary care hospital after decrease in severity of covid 19 strain

7. Commitments:

- i. I have reviewed the clinical protocol and agree that it contains all the necessary information to conduct the study. I will not begin the study until all necessary ethics committee and regulatory approvals have been obtained.
- ii. I agree to conduct the study in accordance with the current protocol. I will not implement any deviation from or changes of the protocol without agreement by the Sponsor and prior review and documented approval or favourable opinion from the ethics committee of the amendment, except where necessary to eliminate an immediate

hazard to the trial subject or when the changes involved are only logistical or administrative in nature.

- iii. I agree to personally conduct or supervise the clinical trial at my site.
- iv. I agree to inform all trial subjects that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent and ethics committee review and approval specified in the New Drugs and Clinical Trials Rules, 2019 and Good Clinical Practices guidelines are met.
- v. I agree to report to the Sponsor all adverse experiences that occur in the course of the investigation(s) in accordance with the regulatory requirements and Good Clinical Practices guidelines.
- vi. I have read and understood the information in the Investigator's brochure, including the potential risks and side effects of the drug.
- vii. I agree to ensure that all associates, colleagues and employees assisting in the conduct of the study are suitably qualified and experienced and they have been informed about their obligations in meeting their commitments in the trial.
- viii. I agree to maintain adequate and accurate records and to make those records available for audit or inspection by the Sponsor, ethics committee, Central Licensing Authority or their authorized representatives, in accordance with regulatory provisions and the Good Clinical Practices guidelines. I will fully cooperate with any study related audit conducted by regulatory officials or authorized representatives of the Sponsor.
- ix. I agree to promptly report to the ethics committee all changes in the clinical trial activities and all unanticipated problems involving risks to human subjects or others.
- x. I agree to inform all serious adverse events to the Central Licensing Authority, sponsor as well as the ethics committee within twenty-four hours of their occurrence. In case, of failure to do so, I shall furnish the reason for the delay to the satisfaction of the Central Licensing Authority along with the report of the serious adverse event
- xi. The report of the serious adverse event, after due analysis, shall also be forwarded by me to the Central Licensing Authority, the Chairperson of the ethics committee and the Head of the institution where the trial has been conducted within fourteen days in accordance with the regulatory requirements.
- xii. I will maintain confidentiality of the identification of all participating subjects and assure security and confidentiality of study data. xiii. I agree to comply with all other requirements, guidelines and statutory obligations as applicable to clinical Investigators participating in clinical trials.

Anushka

8. Signature of Investigator with date.

[Signature]

Principal
Godavari College of Nursing
JALGAON

